Dr. Marshall B. Lucas, MD
Psychiatry (Psychiatry Physician)
8701 New Trails Dr Ste 150
The Woodlands, TX 77381
Who else practices at this address →
Montgomery County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 124
Licensed in Texas since 1991, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: University of Texas Medical School at Houston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
TX license J0080 (first issued 1991; active) -
Addiction Psychiatry Physician
TX license J0080 (first issued 1991; active) -
Child & Adolescent Psychiatry Physician
TX license J0080 (first issued 1991; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- HCA Houston Healthcare Kingwood Kingwood, TX
- HCA Houston Healthcare Conroe Conroe, TX
Medical groups
- Family Psychiatry of the Woodlands PA (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 124
- Services billed
- 1,747
- Patients’ average age
- 57
| Service | Times | Patients |
|---|---|---|
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 374 | 11 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 290 | 47 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 286 | 48 |
| Therapy using electrical currents | 177 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 83 | 33 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 57 | 44 |
| Established patient office or other outpatient visit, 20-29 minutes | 44 | 27 |
| Hospital discharge day management, more than 30 minutes | 30 | 27 |
| Hospital discharge day management, 30 minutes or less | 30 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 36 payments worth $848 in total to this clinician.
| AbbVie Inc. | $278 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $236 |
| Teva Pharmaceuticals USA, Inc. | $125 |
| Corium, LLC | $59.81 |
| Alkermes, Inc. | $48.52 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $34.42 |
| Tris Pharma Inc | $22.87 |
| Otsuka America Pharmaceutical, Inc. | $15.87 |
| Food and Beverage | $848 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 2 companies. The companies reported $123,721 in research payments for these studies, mostly to the institutions running them.
- Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
AbbVie Inc. · Completed · NCT04578756 - Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder
AbbVie Inc. - Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie Inc. - A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie Inc. · Recruiting · NCT06696755 - A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04085172 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder
AbbVie Inc. - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie Inc. · Recruiting · NCT05711394 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.